Archived News

 
ALLG's Highlights at the World Cancer Congress Dec 2014
The ALLG will be at the World Cancer Congress in Melbourne 3–6 December 2014. more ...
 
Chair & CEO Address at AGM Nov 2014
The Chairman's address and the CEO report presented to the members at the Annual General Meeting (AGM) held on 13 November 2014. more ...
 
Thank you to our Fundraising Hero Oct 2014
Thank you and congratulations to Prue Deniz, a fundraising champion. more ...
 
ALLG supports World Lymphoma Day with ongoing commitment to clinical trials Sep 2014
14 September 2014: In support of World Lymphoma Day, the Australasian Leukaemia and Lymphoma Group (ALLG) pledges its ongoing support to deliver clinical trials that will advance the translation of research into finding cures for patients with lymphoma. more ...
 
New era for Australia's leading blood cancer clinical trial group Sep 2014
The Australasian Leukaemia and Lymphoma Group (ALLG) will launch on the 9th October the opening of its new state-of the art head office premises, located at 35 Elizabeth St, Richmond. more ...
 
"Making Hope Real" for Patients with MDS June 2014
'Making hope real' for patients with Myelodysplastic syndromes (MDS) are a group of pre-leukaemic conditions with ineffective blood cell production by the bone marrow. Until recently there were very few treatment options for MDS patients to try to reverse or alter the disease. more ...
 
Australian doctors discover micro molecules to help beat Hodgkin Lymphoma Jan 2014
In collaboration with scientists at the University of Queensland, Translational Research Institute, Brisbane, the ALLG have discovered that a simple blood test can determine how well chemotherapy is working in Hodgkin lymphoma patients. more ...
 
Launch of ALLG Trial Centre July 2013
The ALLG headquarters now includes its own trial centre service; we will no longer outsource our trials to other trial centres. more ...
 
Arsenic – from killer to saviour
The results of an interim analysis of APML4, one of the ALLG's most successful clinical trials, was recently published in Blood, the journal of the American Society of Hematology. more ...
 
Its all in the Blood
In cutting edge research from the ALLG's aggressive lymphoma study 'NHL21', researchers Mark Hertzberg, Maher Gandhi and Colm Keane provide new insights into the role the immune system plays in this disease. In findings recently presented to the 12th International Congress in Malignant Lymphoma in Lugano, Switzerland, they and colleagues demonstrate that a particular type of white blood cell (the 'monocyte') is abnormal in patients with poor-risk Diffuse Large B-cell Lymphoma. Patients with high numbers of abnormal monocytes were more likely to have positive scans after four cycles of therapy. These findings provide a new way of thinking about how lymphoma comes about, and down the track may one day give rise to new avenues for therapy.